Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.

Abstract: Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Abstract: Methods and compounds for conferring site-specific or local immune privilege.

Abstract: Methods and compounds for conferring site-specific or local immune privilege.

Abstract: An air suspension system which includes the ability to adjust the working air volume, pressure, and spring rate of one or more air springs to reduce or eliminate various types of vehicle oscillations. Switchable or variable volume air spring assemblies have the ability to change air spring volumes, which results in changes in air spring rates, and therefore changes in normal loads applied to each wheel. Changes in wheel normal loads change wheel traction (slip) and vehicle dynamics (pitch, roll, yaw displacement, rate and acceleration). The spring rate of one or more of the air spring assemblies is adjusted automatically when a vehicle oscillation is detected. This vehicle oscillation is calculated from the raw vehicle signals, or another vehicle module may detect the oscillation and send a command to the air suspension module to change the spring rates. This changes the natural frequency of the vehicle, dampening the oscillation.

Abstract: A method of controlling a vehicle includes the steps of identifying a lead vehicle with at least one sensor on the vehicle, tracking the lead vehicle with the at least one sensor, and maintaining the vehicle at a predetermined following position from the lead vehicle based on a position of the lead vehicle and a terrain adjacent at least one of the vehicle or the lead vehicle.

Abstract: An air suspension system which includes a Dynamic Load Transfer (DLT) function. DLT is a process of transferring vehicle load, or varying normal loads applied to each wheel of the vehicle, using switchable volume or variable volume air spring assemblies. Switchable or variable volume air spring assemblies have the ability to change air spring volumes, which results in changes in air spring rates, which result in changes in normal loads applied to each wheel. Changes in wheel normal loads change wheel traction (slip) and vehicle dynamics (pitch, roll, yaw displacement, rate and acceleration). Each air spring assembly may have multiple volume air chambers that are switched “on” and “off,” a variable volume air chamber, or the air spring assembly may be coupled with other air springs, or air chambers, that are switched or varied.

Abstract: Methods and compounds for conferring site-specific or local immune privilege.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

Abstract: A vehicle air spring suspension system includes multiple air springs. Each air spring has at least one volume. A valve is fluidly arranged between at least two volumes of the at least one volume of the air springs. The valve is movable between open and closed positions in response to an input. The at least two volumes are fluidly coupled with the valve in the open position. The at least two volumes are fluidly decoupled with the valve in the closed position. At least one vehicle sensor is configured to detect a vehicle attitude condition. A controller is in communication with the valve and the at least one vehicle sensor. The controller is configured to provide the input and selectively adjust the air springs to change the vehicle attitude by raising and/or lowering at least one vehicle wheel relative to a vehicle chassis in response to the input.

Abstract: An air suspension system which includes a Dynamic Load Transfer (DLT) function. DLT is a process of transferring vehicle load, or varying normal loads applied to each wheel of the vehicle, using switchable volume or variable volume air spring assemblies. Switchable or variable volume air spring assemblies have the ability to change air spring volumes, which results in changes in air spring rates, which result in changes in normal loads applied to each wheel. Changes in wheel normal loads change wheel traction (slip) and vehicle dynamics (pitch, roll, yaw displacement, rate and acceleration). Each air spring assembly may have multiple volume air chambers that are switched “on” and “off,” a variable volume air chamber, or the air spring assembly may be coupled with other air springs, or air chambers, that are switched or varied.

Abstract: An air suspension system which includes the ability to adjust the working air volume, pressure, and spring rate of one or more air springs to reduce or eliminate various types of vehicle oscillations. Switchable or variable volume air spring assemblies have the ability to change air spring volumes, which results in changes in air spring rates, and therefore changes in normal loads applied to each wheel. Changes in wheel normal loads change wheel traction (slip) and vehicle dynamics (pitch, roll, yaw displacement, rate and acceleration). The spring rate of one or more of the air spring assemblies is adjusted automatically when a vehicle oscillation is detected. This vehicle oscillation is calculated from the raw vehicle signals, or another vehicle module may detect the oscillation and send a command to the air suspension module to change the spring rates. This changes the natural frequency of the vehicle, dampening the oscillation.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.